Paul Tudor Jones’s Belite Bio BLTE Stock Holding History

Paul Tudor Jones’s Portfolio BLTE Stock Details BLTE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,596	Closed	-$254K	–	3585
2026 Q1	$254K	Buy	+1,596	New	+$268K	﹤0.01%	3237

Other funds holding BLTE

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $7.48B AUM 104.76% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Holocene Advisors New York $44.4B AUM 57.89% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Paul Tudor Jones's BLTE Position: Q2 2026 in Review

Paul Tudor Jones sold out of Belite Bio (BLTE) in Q2 2026, closing a stake of 1,596 shares — an estimated $254K sold.

Paul Tudor Jones first reported a position in BLTE in Q1 2026 and held it in 1 quarter. The position peaked at $254K in Q1 2026. 81 funds tracked by Wall St. Rank hold BLTE as of Q2 2026.

Paul Tudor Jones reported no remaining Belite Bio position as of Q2 2026 after selling out during the quarter.
Paul Tudor Jones sold 1,596 Belite Bio shares in Q2 2026, an estimated $254K.
Paul Tudor Jones first reported a position in Belite Bio in Q1 2026 and held it in 1 quarter.
Paul Tudor Jones's Belite Bio position peaked at $254K in Q1 2026.
81 funds tracked by Wall St. Rank held Belite Bio as of Q2 2026.

Based on Tudor Investment Corp's 13F filing for Q2 2026, filed 14 Aug 2026.